Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIP: Adjuvant Gemcitabine and Cetuximab in Resected Pancreatic Cancer
NCT00395252Phase 2Completed
- Start
- Oct 2006
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of KL-140 in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Disease-Free Survival at 18 months. Started Oct 2006; status: completed.
02
Drugs
KL-140
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00395252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395252.